NEURii will use high-quality data, Artificial Intelligence (AI), and Machine Learning (ML) to deliver initial pilot projects that have the potential to make a meaningful difference to patients’ lives while maintaining data security and public trust.

By combining diverse digital biomarkers that can be acquired non-invasively in real world clinical and non-clinical settings (e.g. speech from conversation) with health data, and analysing them with tailored AI algorithms, NEURii aims to create innovative digital solutions.

NEURii will use real-world data to measure the impact of these projects on the detection, monitoring and treatment of dementia and explore further opportunities to scale up digital health efforts across the UK and beyond.

Dr. Teiji Kimura, Ph.D., Academia and Industry Alliance Officer, Deep Human Biology Learning (DHBL) Office of Eisai, commented:
“Dementia not only has a significant impact on the lives of those living with this disease and their caregivers, but also places a heavy burden on the medical and social security systems.

“We aim to create new digital solutions that will contribute to solving the challenges of dementia by combining the UK’s leadership in this field with our experience and track record of continuously creating innovative treatments in the field of dementia whilst staying true to our human health care concept of giving first thought to patients and the people in the daily living domain.”

It is estimated that more than 55 million people are currently living with dementia in the world and nearly one million in the UK, and this number is expected to grow rapidly.

As well as having a significant impact on the lives of patients and those who care for them (52% of the UK public knows someone who has been diagnosed with a form of dementia),these conditions place significant pressure on health and social care systems.

Providing data-driven solutions that complement existing treatments could help to improve earlier detection and diagnosis, evidence-based treatment decision-making, monitoring of disease progression and maintenance of quality of life.

Paul Wright, Neurodegeneration Translational Challenge Lead at LifeArc, said:
“Identifying ways to prevent dementia and neurodegenerative disease is a key part of our multi-million-pound neurodegeneration program.

“This collaboration is one of many new innovative projects we are involved in to improve the diagnosis of dementia and a positive step towards predicting those who may develop the disease.”

The UK is a leader in digital technology investment and research across areas such as genomics, health data science, AI and ML, with rich and diverse health-related data. NEURii’s model will enable the identification of pioneering data and digital science, the mentoring of talented scientists and the translation of health prototypes into practical and accessible products.

By bringing together the expertise and capabilities of the NEURii collaborators, it is hoped that the novel approach will provide an exciting launch-pad for new transformational digital products that can contribute to solving the ongoing challenges of dementia and neurodegenerative conditions.

Dr Andrea Taylor, Head of Strategic Partnerships at Edinburgh Innovations, the University of Edinburgh’s commercialisation service, said:
“This partnership has been sustained by one core idea – that to meet wickedly complex global challenges such as dementia, new, innovative kinds of international collaboration are required.

“We hope that by bringing together data with global research and industry expertise in this way, we will be eventually able tackle dementia earlier, at a pre-symptomatic stage, reducing the impacts on society and improving the lives of patients and others affected by this cruel condition.”

Dr. Niranjan Bose, Managing Director of Health & Life Sciences at Gates Ventures said:
“AI and other advanced technologies are beginning to play a powerful role in medical research. I’m excited about how the NEURii collaboration will apply these tools to diagnostics research and drug discovery, and contribute to breakthroughs that can improve life for millions of people suffering with dementia and dementia-related illnesses.”

Neurii academic lead Professor Siddharthan Chandran, of the University of Edinburgh, said:
“The University of Edinburgh is delighted to be part of this ambitious cross-sector digital partnership that has, as an explicit goal, the creation of low cost and globally scalable digital tools to predict and monitor dementia.”

Professor Andrew Morris, Director of HDR UK, said:
“Almost one million people in the UK are living with dementia. This new public-private partnership aims to gain a deeper understanding of the disease through trustworthy use of large datasets of anonymised health data in secure environments.

“We will take forward a set of pilot projects and engage with the public. Our aim is to produce new data-driven products that will benefit patients and their families in detecting dementia, predicting its progress and better managing the disease.”

LifeArc operate ISO13485 certified facilities on Edinburgh BioQuarter, in NINE – Health Innovation Centre, and this includes labs dedicated to developing diagnostics. The team specialises in molecular diagnostics and has some of the most modern and comprehensive technologies available.